氯代西布曲明 | 84485-08-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氯代西布曲明
• 中文别名: 氯代诺美婷；氯代西布曲明盐酸盐
• 英文名称: Chloro-sibutramine hydrochloride
• 英文别名: 1-[1-(3,4-dichlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine;hydrochloride
• CAS: 84485-08-5
• 化学式: C17H26Cl3N
• 分子量: 350.7
• InChiKey: RTMMDRRRGLBKDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.81
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
  申请人：Laboratorios del Dr. Esteve, S.A.

  公开号：EP3082782A1

  公开（公告）日：2016-10-26
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
• Implantable sensors, implantable pumps and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070197957A1

  公开（公告）日：2007-08-23

  Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent or a composition that comprises an anti-scarring agent to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
• Electrical devices and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070198063A1

  公开（公告）日：2007-08-23

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
• SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：US20160310500A1

  公开（公告）日：2016-10-27

  The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain.